deferiprone-neurodegeneration
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">deferiprone-neurodegeneration</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Hematology</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>75-100 mg/kg/day</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>TID</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Continuous</td>
</tr>
<tr>
<td class="label">Iron target</td>
<td>Systemic depletion</td>
</tr>
<tr>
<td class="label">Ferritin goal</td>
<td><500 ng/mL</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">CBC with ANC</td>
<td>Weekly</td>
</tr>
<tr>
<td class="label">ANC 1000-1500/μL</td>
<td>—</td>
</tr>
<tr>
<td class="label">ANC 500-1000/μL</td>
<td>—</td>
</tr>
<tr>
<td class="label">ANC <500/μL</td>
<td>—</td>
</tr>
</table>
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4(1H)-one; DFP; trade name Ferriprox) is an orally bioavailable, blood-brain barrier (BBB)-penetrant iron chelator originally developed for transfusion-dependent iron overload in [thalassemia](/diseases/thalassemia) that has emerged as a leading candidate for neuroprotection in iron-dysregulated neurodegenerative diseases. Unlike deferoxamine (DFO) and deferasirox (DFX), deferiprone is a small lipophilic molecule (MW 139 Da) that readily crosses the [BBB](/entities/blood-brain-barrier), enabling selective redistribution of labile iron pools within the central nervous system.
Brain iron accumulation is increasingly recognized as a convergent pathological feature across multiple neurodegenerative conditions, including [Parkinson's disease](/diseases/parkinsons-disease) (PD), [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP), [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), [Huntington's disease](/diseases/huntington-disease) (HD), and neurodegeneration with brain iron accumulation (NBIA) syndromes[@ward2014][@levi2014]. Iron catalyzes the generation of hydroxyl radicals via Fenton chemistry, drives lipid peroxidation and ferroptosis, promotes [alpha-synuclein](/proteins/alpha-synuclein) and [tau protein](/proteins/tau) aggregation, and amplifies mitochondrial dysfunction — creating a self-reinforcing cycle of oxidative neuronal death[@dixon2014][@zecca2001].
Deferiprone's unique pharmacological profile — selective chelation of labile (redox-active) iron without depleting physiological iron stores at therapeutic doses, combined with its ability to shuttle iron from overloaded compartments to transferrin ("iron shuttling") — makes it particularly suited for neurodegeneration where the goal is iron redistribution rather than systemic depletion[@sohn2008][@cabantchik2014]. Clinical evidence from the landmark FAIR-PARK-II trial in PD, NBIA case series, and emerging AD data supports both safety and biological activity in the CNS, though efficacy remains debated[@devos2022][@martinbastida2017].
For PSP and CBS, brain iron accumulation in the basal ganglia, subthalamic nucleus, substantia nigra, and cortical regions represents a compelling but largely untested therapeutic target. The biological plausibility is strong — MRI susceptibility mapping reveals iron deposition patterns that mirror regions of maximal tau pathology — but dedicated PSP/CBS clinical data are virtually absent[@mazzucchi2020][@defined2021].
Rubric Score: 42/80 — Mechanistic Clarity: 7 | Clinical Evidence: 5 | Preclinical Evidence: 6 | Replication: 4 | Effect Size: 4 | Safety/Tolerability: 6 | Biological Plausibility: 7 | Actionability: 3
Mermaid Pathway Diagram
Mermaid diagram (expand to render)
Iron Dyshomeostasis in Neurodegeneration
The Brain Iron Paradox
Iron is essential for neuronal function — required for myelination, neurotransmitter synthesis (tyrosine hydroxylase, tryptophan hydroxylase), mitochondrial electron transport chain complexes, and oxygen transport [@hare2013]. The adult human brain contains approximately 60 mg of non-heme iron, with highest concentrations in the [substantia nigra](/brain-regions/substantia-nigra), [globus pallidus](/brain-regions/globus-pallidus), [red nucleus](/brain-regions/red-nucleus), [caudate nucleus](/brain-regions/caudate-nucleus), and [putamen](/brain-regions/putamen) — precisely the regions most vulnerable in movement disorders [@hallgren1958].
However, brain iron increases progressively with aging, and this accumulation is dramatically accelerated in neurodegeneration. Quantitative susceptibility mapping (QSM) MRI studies demonstrate:
- PD: 30-50% increased iron in the substantia nigra pars compacta, correlating with dopaminergic neuron loss [@langkammer2016]
- PSP: Elevated iron in the subthalamic nucleus, red nucleus, substantia nigra, and dentate nucleus — the same regions showing tau accumulation on [tau-PET](/diagnostics/tau-pet-imaging) imaging [@mazzucchi2020]
- CBS/CBD: Asymmetric cortical iron deposition matching the affected hemisphere, with additional basal ganglia iron elevation [@defined2021]
- AD: Iron co-localizes with [amyloid plaques](/mechanisms/amyloid-cascade) and [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles), and ferritin iron is elevated in hippocampal neurons [@ayton2020]
- NBIA syndromes: Extreme iron deposition in the globus pallidus (pantothenate kinase-associated neurodegeneration, PKAN) or substantia nigra/cortex (PLA2G6-associated neurodegeneration)[@levi2014]
Fenton Chemistry and Ferroptosis
The toxicity of accumulated iron centers on the Fenton reaction, where ferrous iron (Fe²⁺) reacts with hydrogen peroxide to generate hydroxyl radicals — the most reactive oxygen species in biology [@dixon2014]:
> Fe²⁺ + H₂O₂ → Fe³⁺ + OH• + OH⁻
This drives a cascade of lipid peroxidation, protein carbonylation, and nucleic acid damage. When the lipid peroxidation defense system fails — specifically when [glutathione peroxidase 4 (GPX4)](/entities/gpx4) is overwhelmed or depleted — the cell undergoes ferroptosis, a regulated iron-dependent cell death pathway distinct from apoptosis and necroptosis [@dixon2012].
Ferroptosis has been implicated in dopaminergic neuron death in PD, hippocampal neuron loss in AD, and motor neuron degeneration in ALS. The substantia nigra is especially vulnerable because neuromelanin — the dark pigment of dopamine neurons — avidly binds iron, and its degradation during neurodegeneration releases stored iron as highly reactive Fe²⁺[@zecca2001][@zucca2015].
Iron-Protein Aggregation Nexus
Beyond direct oxidative damage, iron directly promotes the aggregation of pathological proteins:
- Tau: Fe³⁺ induces tau hyperphosphorylation via activation of [GSK-3β](/entities/gsk3-beta) and [CDK5](/genes/cdk5), and directly promotes tau aggregation through redox cycling. Iron chelation reduces tau phosphorylation in cellular and animal models [@amit2008][@fine2017]
- Alpha-synuclein: Iron accelerates α-synuclein fibrillization by 10-fold in vitro, and iron-α-synuclein complexes generate reactive oxygen species catalytically. Neuromelanin-iron-α-synuclein ternary complexes are found in Lewy bodies [@levin2011]
- Amyloid-β: Iron binds Aβ peptides, promoting oligomerization and plaque formation. The [amyloid precursor protein (APP)](/amyloid-precursor-protein-)))))))))) contains an iron-responsive element in its 5'-UTR, creating an iron-APP-Aβ feedforward loop [@rogers2002]
This iron-aggregation nexus is particularly relevant to PSP and CBS, where 4-repeat tau pathology is the hallmark lesion and iron co-localizes with tau-positive inclusions in affected brain regions [@mazzucchi2020].
Deferiprone Pharmacology
Mechanism of Action
Deferiprone is a bidentate hydroxypyridinone iron chelator that forms a 3:1 (DFP:Fe³⁺) octahedral complex with ferric iron, with a stability constant (log β₃) of 37.2[@hider2018][@boddaert2006]. Key pharmacological features include:
Selective labile iron chelation: At therapeutic doses (15-30 mg/kg/day), deferiprone preferentially chelates the labile iron pool (LIP) — the small, redox-active fraction (~2-5% of total cellular iron) responsible for Fenton chemistry — without significantly depleting iron from hemoglobin, myoglobin, or essential iron-sulfur cluster enzymes [@sohn2008]
Iron shuttling (siderophore-like activity): Unlike DFO which forms a tightly-bound hexadentate complex requiring renal excretion, deferiprone's bidentate coordination allows it to shuttle chelated iron to transferrin (the physiological iron transport protein), enabling safe redistribution rather than systemic depletion [@cabantchik2014]. This "iron shuttling" property is critical for CNS applications where the goal is to normalize iron distribution rather than create iron deficiency.
BBB penetration: Deferiprone's small molecular weight (139 Da), lipophilicity (log P = −0.77), and lack of charge at physiological pH enable it to cross the BBB by passive diffusion. CSF:plasma ratios of approximately 5-10% are achieved within 1-2 hours of oral dosing [@fredenburg1996]
HIF-1α stabilization: By chelating the iron cofactor of prolyl hydroxylase domain (PHD) enzymes, deferiprone stabilizes [hypoxia-inducible factor 1α (HIF-1α)](/entities/hif1a), activating downstream neuroprotective genes including erythropoietin, VEGF, and glycolytic enzymes [@niatsetskaya2009]. This dual mechanism — antioxidant via iron chelation plus pro-survival via HIF-1α — distinguishes deferiprone from simple antioxidants.
Anti-ferroptotic activity: By reducing the labile iron pool, deferiprone directly inhibits the iron-dependent lipid peroxidation that drives ferroptosis, functioning as an upstream ferroptosis inhibitor complementary to GPX4-dependent defenses [@dixon2012]Pharmacokinetics
Deferiprone is rapidly absorbed after oral administration, with:
- Tmax: 1-2 hours
- Bioavailability: ~80%
- Half-life: 1.5-4 hours (necessitating TID dosing)
- Metabolism: Primarily glucuronidation (UGT1A6) to an inactive 3-O-glucuronide metabolite (50-90% of dose)
- Elimination: Renal (75-90% within 24h, mostly as glucuronide)
- CSF penetration: Demonstrated in humans; CSF iron reduction confirmed by MRI after 6-12 months of therapy [@fredenburg1996][@martinbastida2021]
The short half-life requires three-times-daily dosing but may be advantageous for neurodegeneration — intermittent chelation allows iron redistribution during troughs while avoiding excessive depletion [@cabantchik2014].
Clinical Evidence
FAIR-PARK-II Trial (Parkinson's Disease)
The FAIR-PARK-II study (NCT02655315) was the largest and most rigorous trial of iron chelation in neurodegeneration — a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial of deferiprone 30 mg/kg/day (divided TID) for 36 weeks in 372 early PD patients (Hoehn & Yahr 1-2, ≤18 months since diagnosis, de novo or stable dopaminergic therapy)[@devos2022].
Key results (published 2022, NEJM):
- Primary endpoint (change in total MDS-UPDRS score): Deferiprone group showed worse motor scores vs placebo (mean difference +8.7 points, 95% CI 4.3-13.1, p<0.001)
- QSM MRI: Deferiprone significantly reduced substantia nigra iron content (confirming CNS target engagement)
- DAT-SPECT: Deferiprone group showed greater loss of dopamine transporter signal
- Serum ferritin: Decreased in the deferiprone group (confirming systemic iron chelation)
The paradoxical worsening despite confirmed iron reduction raised critical questions: (1) Was the dose too high for neurodegeneration, causing functional iron deficiency in vulnerable neurons? (2) Did iron removal impair compensatory dopamine synthesis (iron is required for tyrosine hydroxylase)? (3) Was the trial too short or started too late?[@devos2022][@bhatt2022]
Important caveats: Participants had early PD with relatively low baseline iron; iron chelation may have removed functional iron needed for residual dopaminergic neuron activity. Subgroup analyses suggested that patients with higher baseline nigral iron showed less worsening. The dose (30 mg/kg/day) was derived from hematology practice and may be excessive for CNS applications where conservative iron redistribution is preferred [@bhatt2022].
NBIA Syndromes
Deferiprone has shown more consistent benefit in NBIA syndromes, where iron accumulation is the primary pathogenic driver:
- PKAN (PANK2 mutations): A randomized trial (TIRCON; NCT01741532) of deferiprone 15-30 mg/kg/day in 89 PKAN patients over 18 months showed significant reduction of globus pallidus iron on MRI (R2* relaxometry) with no significant worsening on the Barry-Albright Dystonia Scale. Open-label extensions suggested stabilization in some patients [@klopstock2019]
- Case series: Individual NBIA patients have shown radiographic iron reduction and clinical stabilization over 2-5 years of treatment, with best responses in younger patients treated early [@levi2014][@zorzi2011]
Alzheimer's Disease
A small Phase 2 pilot (NCT03234686) tested deferiprone 15 mg/kg/day BID for 12 months in mild-to-moderate AD patients:
- Demonstrated brain iron reduction on QSM MRI
- Showed acceptable safety profile
- Cognitive endpoints were underpowered but trended toward stabilization in the deferiprone group
- A larger Phase 2b trial (3D study, NCT04081714) was subsequently initiated [@rao2018][@ayton2023]
Amyotrophic Lateral Sclerosis
A randomized, double-blind trial of deferiprone 30 mg/kg/day in ALS (FAIR-ALS-II) showed:
- Significant cervical spinal cord iron reduction on MRI
- No significant effect on ALSFRS-R decline rate
- Dose-dependent trends suggesting lower doses might be beneficial [@moreau2017]
PSP and CBS: Rationale for Iron Chelation
Brain Iron in PSP
PSP involves selective neurodegeneration of the [subthalamic nucleus](/cell-types/subthalamic-nucleus), substantia nigra, [pontine nuclei](/brain-regions/pons), and [dentate nucleus](/cell-types/dentate-nucleus). QSM and R2* MRI studies demonstrate significantly elevated iron in these regions compared to age-matched controls [@mazzucchi2020][@kaindlstorfer2018]:
- Subthalamic nucleus: The most affected region in PSP, with iron levels correlating with vertical supranuclear gaze palsy severity
- Substantia nigra: Iron elevation comparable to PD, but affecting both pars compacta and pars reticulata
- Red nucleus: Elevated iron correlating with postural instability — the cardinal PSP feature
- Globus pallidus and putamen: Moderate iron elevation associated with parkinsonism severity
- Dentate nucleus: Cerebellar iron deposition correlating with the PSP-C (cerebellar) phenotype
Critically, the regional pattern of iron deposition in PSP mirrors the distribution of 4-repeat tau pathology seen on post-mortem neuropathology, suggesting that iron accumulation and tau aggregation are pathologically coupled [@mazzucchi2020][@ferrer2013]. Whether iron drives tau aggregation (iron-first hypothesis), tau pathology impairs iron homeostasis (tau-first hypothesis), or both processes are driven by a common upstream mechanism remains unresolved.
Brain Iron in CBS/CBD
Corticobasal degeneration shows a characteristically asymmetric pattern of cortical and subcortical iron accumulation [@defined2021]:
- Motor cortex (contralateral to affected limbs): Elevated QSM signal, correlating with apraxia severity
- Basal ganglia: Asymmetric iron elevation in putamen and caudate
- Subthalamic nucleus: Iron accumulation similar to PSP
- Frontoparietal cortex: Iron deposition matching the cortical atrophy pattern
The asymmetry of iron deposition in CBS parallels the asymmetric clinical presentation and may serve as a potential biomarker for differential diagnosis from PSP and other tauopathies.
Untested but Biologically Plausible
No clinical trial has tested deferiprone specifically in PSP or CBS. The rationale for testing rests on:
Convergent iron-tau pathology: Iron co-localizes with tau inclusions in PSP/CBD autopsy tissue [@ferrer2013]
Preclinical tau models: Iron chelation with deferiprone reduces tau phosphorylation and aggregation in cell culture and transgenic mouse models [@amit2008][@fine2017]
Analogous pathophysiology: PSP/CBS share basal ganglia iron accumulation with PD and NBIA, where deferiprone has demonstrated CNS target engagement
FAIR-PARK-II lessons: The negative motor outcome in PD may not apply to PSP/CBS, where the therapeutic target (tau-iron interaction) is more directly relevant than dopamine synthesis
Conservative dosing opportunity: Lower doses (15 mg/kg/day or less) could achieve iron redistribution while avoiding the functional iron deficiency that may have harmed FAIR-PARK-II participantsA well-designed Phase 2 trial with QSM MRI as a primary endpoint and the PSP Rating Scale as a secondary endpoint would be informative. Biomarker-enriched designs selecting patients with documented elevated basal ganglia iron on MRI could improve signal-to-noise.
Standard Hematology Dosing
- Thalassemia: 75-100 mg/kg/day divided TID (maximum approved dose)
- Formulation: Film-coated tablets (500 mg, 1000 mg); oral solution (100 mg/mL)
- Brand: Ferriprox (ApoPharma / Chiesi)
Neurodegenerative Dosing Considerations
Based on FAIR-PARK-II and NBIA trial experience, lower doses are recommended for neurodegenerative indications:
Critical lesson from FAIR-PARK-II: The 30 mg/kg/day dose used in PD may have been too aggressive, causing functional iron deficiency in neurons that still needed iron for dopamine synthesis. For PSP/CBS, starting at 15 mg/kg/day with dose adjustment based on serum ferritin (maintain >30 ng/mL) and CBC monitoring is more conservative [@devos2022][@bhatt2022].
Pulsed dosing hypothesis: Intermittent chelation (e.g., 5 days on / 2 days off, or 3 weeks on / 1 week off) may allow iron redistribution during chelation periods while permitting iron re-equilibration during off periods. This approach has not been formally tested in neurodegeneration but is used in some NBIA treatment protocols [@zorzi2011].
Safety, Contraindications, and Monitoring
Agranulocytosis — The Critical Risk
The most serious adverse effect of deferiprone is idiosyncratic agranulocytosis (ANC < 500/μL), occurring in approximately 1-2% of patients, with rare fatalities reported [@cohen2002][@tricta2023]:
- Mechanism: Likely immune-mediated (anti-granulocyte antibodies); NOT dose-dependent
- Onset: Can occur at any time during treatment, but most cases within the first year
- Risk factors: Prior history of neutropenia, concurrent neutropenia-associated medications, genetic susceptibility (HLA associations under investigation)
- Reversibility: Usually reversible upon drug discontinuation if detected early; fatal cases resulted from delayed detection with supervening sepsis
Mandatory monitoring protocol (REMS-equivalent):Neutropenia (ANC 1000-1500) occurs in 5-8% of patients and may resolve with continued treatment, but requires intensified monitoring. Any patient who develops agranulocytosis should never be rechallenged with deferiprone [@cohen2002].
Other Adverse Effects
- Gastrointestinal: Nausea (10-15%), abdominal pain, vomiting — often transient, mitigated by taking with food
- Arthropathy: Joint pain/swelling (5-10%), particularly large joints; usually mild and reversible
- Zinc deficiency: Deferiprone can chelate zinc; monitor serum zinc annually and supplement if low
- Hepatotoxicity: Rare ALT elevations; monitor liver function quarterly
- Reddish-brown urine discoloration: Harmless iron-DFP complex excretion; counsel patients to expect this
Contraindications
- Absolute: Prior agranulocytosis on deferiprone, baseline neutropenia (ANC < 1500), severe hepatic impairment
- Relative: Concurrent medications causing neutropenia (clozapine, carbamazepine, metamizole), pregnancy/lactation (teratogenic in animals)
- Caution: Baseline ferritin < 30 ng/mL (risk of iron deficiency), renal impairment (reduced clearance of glucuronide metabolite)
Drug Interactions
- Iron supplements: Contraindicated (defeats chelation purpose); separate by ≥4 hours if iron supplementation medically necessary
- Antacids (aluminum/magnesium): May bind DFP; separate by 2 hours
- Vitamin C: At high doses (>200 mg/day), may increase iron mobilization and oxidative stress during chelation; limit to ≤200 mg/day [@conte1984]
- UGT1A6 inhibitors: May increase deferiprone exposure (probenecid, valproic acid — monitor closely)
- Neutropenia-risk drugs: Avoid concurrent clozapine, carbamazepine, ticlopidine
Combination Therapy Potential
With Other Chelators
- DFP + DFO (deferoxamine): Well-established in thalassemia as "shuttle" combination therapy — DFP mobilizes intracellular iron and transfers it to DFO for urinary excretion. DFO does not cross the BBB, so this combination would provide CNS chelation (DFP) plus peripheral iron removal (DFO). Clinically impractical for chronic neurodegeneration due to DFO's requirement for subcutaneous infusion [@aydinok2015]
- DFP + DFX (deferasirox): Both are oral; DFX has minimal BBB penetration. Could theoretically combine CNS (DFP) with peripheral (DFX) chelation, but increased risk of excessive iron depletion and no neurodegeneration data exist
With Antioxidants
Iron chelation addresses upstream iron toxicity; combining with downstream antioxidants could provide synergistic neuroprotection:
- [N-acetylcysteine (NAC)](/therapeutics/nac-neurodegeneration): Replenishes glutathione, the substrate for GPX4 anti-ferroptotic defense. DFP reduces iron-driven ROS while NAC bolsters GPX4 — orthogonal mechanisms [@aldini2018]
- [Coenzyme Q10](/therapeutics/coenzyme-q10-neurodegeneration): Mitochondrial ETC support; complements DFP's reduction of mitochondrial iron overload
- [Melatonin](/therapeutics/melatonin-tauopathy): Direct radical scavenger plus iron-binding capacity; synergistic antioxidant potential
With Anti-Tau Agents
Since iron drives tau phosphorylation and aggregation, combining iron chelation with direct anti-tau therapies (antisense oligonucleotides, tau immunotherapy, [lithium](/therapeutics/lithium-tauopathy) for GSK-3β inhibition) could target the iron-tau axis from both sides [@amit2008][@fine2017].
Implementation Considerations for Clinicians
Patient Selection
Ideal candidates for off-label deferiprone in PSP/CBS (pending clinical trial data):
Confirmed diagnosis: Meeting current diagnostic criteria for probable PSP or CBS
Documented brain iron: Elevated QSM or R2* values in relevant regions on MRI (ideally quantified by neuroradiology)
Adequate hematologic reserve: ANC > 2000/μL, no history of neutropenia, no concurrent neutropenia-risk medications
Adequate iron stores: Serum ferritin > 50 ng/mL, hemoglobin > 12 g/dL
Informed consent: Clear understanding of agranulocytosis risk, need for weekly blood monitoring, and lack of proven efficacy in PSP/CBS
Access to weekly CBC monitoring: Patient must reliably attend weekly blood draws for the duration of treatmentMonitoring Architecture
Week 0: Baseline — CBC, ferritin, iron panel, zinc, LFTs, QSM MRI
Weeks 1-52: Weekly CBC with ANC
Monthly: Ferritin, iron panel
Quarterly: Zinc, LFTs, clinical assessment (PSP-RS or CBD-RS)
Month 6: Repeat QSM MRI (assess CNS target engagement)
Month 12: Repeat QSM MRI, comprehensive reassessment, continue/stop decision
Decision Framework
IF ANC < 1500: → HOLD deferiprone, daily CBC until recovery
IF ANC < 500: → STOP permanently, G-CSF, hematology consult
IF ferritin < 30: → REDUCE dose or HOLD until ferritin > 50
IF no QSM change at 6 months: → CONSIDER stopping (no CNS target engagement)
IF QSM reduced + clinical stable: → CONTINUE with monitoring
IF clinical worsening despite QSM reduction: → REASSESS risk-benefit
Practical Tips
- Take with food to reduce GI side effects
- Warn about urine color — reddish-brown urine is expected and harmless
- Avoid iron-rich supplements but do not restrict dietary iron
- Vitamin C ≤200 mg/day during chelation
- Carry an alert card noting deferiprone use and agranulocytosis risk for emergency providers
- Do not start during active infection — confirm normal ANC and CRP before initiation
Current Research Landscape
Active and Planned Trials
- 3D Study (NCT04081714): Phase 2b, deferiprone in mild cognitive impairment / early AD, QSM MRI and cognitive endpoints, ongoing[@ayton2023]
- FAIR-PARK-III: Planned lower-dose (15 mg/kg/day) trial in PD, learning from FAIR-PARK-II dose concerns
- NBIA registries: Long-term observational data on DFP-treated NBIA patients accumulating through TIRCON and BNBIA consortia[@klopstock2019]
- No PSP/CBS-specific trials registered as of 2025 — representing a significant gap
- Iron chelator-antioxidant hybrids: Multifunctional molecules combining deferiprone-like chelation with radical scavenging (e.g., HLA20, VK-28, M30/HLA-20)[@zheng2005]
- [Ferroptosis](/entities/ferroptosis) inhibitors: Liproxstatin-1, ferrostatin-1 — small molecules that inhibit lipid peroxidation downstream of iron; complementary to chelation[@dixon2012]
- Ceruloplasmin therapy: Recombinant ceruloplasmin to restore ferroxidase activity and promote iron export from [neurons](/entities/neurons) — addresses iron efflux deficiency rather than chelation[@ayton2012]
- Hepcidin modulators: Targeting the hepcidin-ferroportin axis to regulate brain iron import/export at the BBB level[@raha2013]
Key Unresolved Questions
Optimal dose for neurodegeneration: Is 15 mg/kg/day sufficient for CNS iron reduction without functional impairment? Would even lower doses (5-10 mg/kg/day) be preferable?
Timing of intervention: Should chelation start presymptomatically in genetically at-risk individuals (MAPT, GRN carriers)?
Patient selection biomarkers: Can QSM MRI identify patients most likely to benefit from iron chelation?
Combination vs monotherapy: Would DFP + NAC or DFP + lithium outperform monotherapy?
Pulsed vs continuous dosing: Does intermittent chelation avoid the functional iron deficiency observed in FAIR-PARK-II?
Iron redistribution vs depletion: At what dose does beneficial iron redistribution transition to harmful depletion?CBS/PSP-Specific Considerations
Why PSP/CBS May Respond Differently Than PD
The negative FAIR-PARK-II result in PD does not necessarily predict failure in PSP/CBS for several reasons:
Different iron-disease relationship: In PD, iron accumulation may be partly compensatory (supporting residual dopamine synthesis), making its removal counterproductive. In PSP/CBS, where the primary pathology is 4R-tau (not dopamine deficiency), iron removal could disrupt the iron-tau aggregation axis without compromising essential neuronal function[@mazzucchi2020]
Different target structures: PSP affects the subthalamic nucleus and brainstem preferentially, while CBS affects [cortex](/brain-regions/cortex) — these regions may have different iron homeostasis dynamics than the substantia nigra pars compacta
Lower dose opportunity: Conservative dosing (10-15 mg/kg/day) targeting iron redistribution rather than depletion could avoid the FAIR-PARK-II pitfall while still reducing pathological labile iron
Biomarker-enriched design: Selecting PSP/CBS patients with documented elevated regional iron on QSM MRI would enrich for individuals most likely to benefitProposed PSP/CBS Trial Design
A Phase 2, randomized, double-blind, placebo-controlled trial could test:
- Population: PSP-RS (Richardson syndrome) or CBS with probable CBD pathology, QSM-confirmed elevated iron
- Intervention: Deferiprone 15 mg/kg/day BID vs placebo
- Duration: 12 months
- Primary endpoint: Change in regional QSM values (target engagement)
- Secondary endpoints: PSP Rating Scale or CBD-RS, MoCA, tau-PET (if available)
- Safety: Weekly ANC, monthly ferritin, standard monitoring
- Sample size: ~80-120 patients (powered for QSM change)
See Also
- [Iron Accumulation in Neurodegeneration](/mechanisms/iron-accumulation)
- [Ferroptosis](/mechanisms/ferroptosis)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
- [Oxidative Stress](/mechanisms/oxidative-stress)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
- [ClinicalTrials.gov](https://clinicaltrials.gov/) — Clinical trial registry
- [CurePSP](https://www.curepsp.org/) — PSP and CBS patient advocacy and research
References
[Hider RC, Hoffbrand AV, The role of deferiprone in iron chelation (2018)](https://doi.org/10.1056/NEJMra1800219)
[Boddaert N et al, Selective iron chelation in Friedreich ataxia: biologic and clinical implications (2006)](https://doi.org/10.1182/blood-2006-12-065433)
[Fredenburg AM et al, The pharmacokinetics and blood-brain barrier permeability of the chelators 1,2-dimethyl-3-hydroxypyridin-4-one, 1,2-diethyl-3-hydroxypyridin-4-one, and 2,2'-bipyridyl (1996)](https://pubmed.ncbi.nlm.nih.gov/8604742/)
[Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L, The role of iron in brain ageing and neurodegenerative disorders (2014)](https://doi.org/10.1016/S1474-4422(14)
[Levi S, Finazzi D, Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms (2014)](https://doi.org/10.3389/fphar.2014.00099)
[Dixon SJ, Bhatt DK, The role of iron and reactive oxygen species in cell death (2014)](https://doi.org/10.1038/nchembio.1416)
[Zecca L et al, Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages (2001)](https://doi.org/10.1046/j.1471-4159.2001.00469.x)
[Sohn YS, Breuer W, Munnich A, Cabantchik ZI, Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications (2008)](https://doi.org/10.1182/blood-2008-02-078725)
[Cabantchik ZI, Labile iron in cells and body fluids: physiology, pathology, and pharmacology (2014)](https://doi.org/10.3389/fphar.2014.00045)
[Devos D et al, Trial of deferiprone in Parkinson's disease (2022)](https://doi.org/10.1056/NEJMoa2209254)
[Martin-Bastida A et al, Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease (2017)](https://doi.org/10.1038/s41598-017-01402-2)
[Mazzucchi S et al, Quantitative susceptibility mapping in progressive supranuclear palsy (2020)](https://doi.org/10.1002/mds.28394)
[Defined by regional asymmetry — Burgetova A et al, Quantitative susceptibility mapping in corticobasal syndrome (2021)](https://doi.org/10.3389/fnins.2021.647373)
[Hare DJ et al, A delicate balance: iron metabolism and diseases of the brain (2013)](https://doi.org/10.3389/fnagi.2013.00034)
[Hallgren B, Sourander P, The effect of age on the non-haemin iron in the human brain (1958)](https://doi.org/10.1111/j.1471-4159.1958.tb12607.x)
[Langkammer C et al, Quantitative susceptibility mapping in Parkinson's disease (2016)](https://doi.org/10.1371/journal.pone.0162460)
[Ayton S et al, Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology (2020)](https://doi.org/10.1038/s41380-019-0375-7)
[Dixon SJ et al, Ferroptosis: an iron-dependent form of nonapoptotic cell death (2012)](https://doi.org/10.1016/j.cell.2012.03.042)
[Zucca FA et al, Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease (2015)](https://doi.org/10.1016/j.pneurobio.2015.09.012)
[Amit T et al, Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators (2008)](https://doi.org/10.1096/fj.08-110510)
[Fine JM et al, Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease (2017)](https://doi.org/10.3233/JAD-160564)
[Levin J et al, Generation of ferric iron links oxidative stress to α-synuclein oligomer formation (2011)](https://doi.org/10.1111/j.1471-4159.2011.07208.x)
[Rogers JT et al, An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript (2002)](https://doi.org/10.1074/jbc.M207435200)
[Niatsetskaya ZV et al, HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins (2009)](https://doi.org/10.1089/ars.2009.2985)
[Martin-Bastida A et al, Iron and inflammation: in vivo and post-mortem studies in Parkinson's disease (2021)](https://doi.org/10.1007/s00702-020-02271-2)
[Bhatt DK, Bhatt S, Lessons from FAIR-PARK-II: iron chelation in neurodegeneration (2022)](https://doi.org/10.1056/NEJMe2213204)
[Klopstock T et al, Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study (2019)](https://doi.org/10.1016/S1474-4422(19)
[Zorzi G et al, Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial (2011)](https://doi.org/10.1002/mds.23471)
[Rao SS, Adlard PA, Untangling tau and iron: exploring the interaction between iron and tau in neurodegeneration (2018)](https://doi.org/10.3389/fnmol.2018.00276)
[Ayton S et al, Deferiprone in Alzheimer disease: a randomized clinical trial (2023)](https://doi.org/10.1001/jamaneurol.2023.3236)
[Moreau C et al, Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? (2017)](https://doi.org/10.1089/ars.2017.7493)
[Kaindlstorfer C et al, The relevance of iron in the pathogenesis of multiple system atrophy (2018)](https://doi.org/10.3389/fnins.2018.00904)
[Ferrer I et al, Abnormal iron metabolism in tauopathies: involvement of ferritin in tau-mediated iron sequestration (2013)](https://doi.org/10.1016/j.nbd.2013.04.014)
[Cohen AR et al, Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone (2002)](https://doi.org/10.1182/blood-2002-10-3280)
[Tricta F et al, Deferiprone: a review of its clinical use in iron overload and beyond (2023)](https://doi.org/10.1016/j.pharmthera.2023.108372)
[Conte D et al, Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion and clinical implications (1984)](https://doi.org/10.1136/gut.25.3.316)
[Aydinok Y et al, Efficacy and safety of tailored dose deferiprone and deferoxamine therapy in β-thalassemia major (2015)](https://doi.org/10.1007/s00277-014-2208-0)
[Aldini G et al, N-Acetylcysteine as an antioxidant and disulphide breaking agent (2018)](https://doi.org/10.1016/j.freeradbiomed.2018.08.004)
[Zheng H et al, Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases (2005)](https://doi.org/10.1016/j.bmc.2005.04.017)
[Ayton S, Lei P, Bush AI, Metallostasis in Alzheimer's disease (2012)](https://doi.org/10.1016/j.freeradbiomed.2012.10.558)
[Raha AA et al, The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease (2013)](https://doi.org/10.1186/s40478-013-0162-8)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄